A synthetic analog of the endogenous immune peptide tuftsin, developed in Russia and studied primarily for anxiolytic and cognitive effects. Interesting mechanism, meaningful Russian clinical record, limited Western replication.
Regulatory notice: Selank is not an FDA-approved drug and is not currently on FDA’s 503A Bulks List. FDA’s Pharmacy Compounding Advisory Committee reviewed a separate group of peptides for the list on July 23–24, 2026; Selank was not among them.
This page is educational and is not medical advice. Whether any therapy is appropriate is a clinical decision — talk to a PepScribe clinician to discuss your situation and options.
Selank is a synthetic 7-amino-acid peptide developed in the early 1990s by Seredenin, Kozlovskaya, and colleagues at the Institute of Molecular Genetics of the Russian Academy of Sciences. It’s a modified analog of tuftsin, a naturally occurring tetrapeptide that your body produces from immunoglobulin G (IgG). The modification adds a D-amino acid and a Pro-Gly-Pro tail that significantly extends its half-life compared to native tuftsin.
Selank is approved in Russia as a pharmaceutical for the treatment of generalized anxiety disorder (GAD) and neurasthenia. The research interest outside Russia centers on its unusual dual action, it appears to modulate both neurological and immune pathways, which is uncommon among anxiolytic compounds.
A 2008 study by Seredenin and Kozlovskaya published in the Bulletin of Experimental Biology and Medicine found that Selank modulates GABA metabolism through enkephalinase inhibition, increasing endogenous GABA levels. Unlike benzodiazepines, which directly bind GABA-A receptors, Selank’s indirect mechanism produces anxiolytic effects without the sedation or dependence risks observed in preclinical models.
Preclinical research by Seredenin et al. (2010, Bulletin of Experimental Biology and Medicine) indicated that Selank increases BDNF expression in the hippocampus of rat models. BDNF is one of the most studied biomarkers in cognitive neuroscience, it’s involved in neuroplasticity, learning, memory formation, and mood regulation.
Research by Kozlovskii and Danchev (2003, Bulletin of Experimental Biology and Medicine) demonstrated that Selank influences serotonin and dopamine metabolism in rat brain tissue, stabilizing the balance between these neurotransmitters. The effect on serotonin turnover was observed in the frontal cortex and hippocampus, regions associated with mood and anxiety processing.
As a tuftsin analog, Selank retains some of its parent peptide’s immune-modulating properties. Research by Ershov et al. (2009, Bulletin of Experimental Biology and Medicine) found that Selank influences the expression of 84 immune-related genes in human blood cells, including cytokine and chemokine pathways. Its primary clinical interest is neurological, but the immune effects are an active research area.
Most mechanistic data comes from preclinical research and the Russian pharmaceutical approval process. Western peer-reviewed clinical data is limited.
Selank has pharmaceutical approval in Russia, which means clinical data exists, though much of it is published in Russian-language journals with limited accessibility in Western databases.
The Russian clinical data supporting Selank’s approval for GAD was reviewed by Seredenin and Kozlovskaya (2012, Eksperimental’naya i Klinicheskaya Farmakologiya). Russian clinical reports describe Selank as producing anxiolytic signals in the populations studied without the sedation, cognitive impairment, or dependence associated with benzodiazepines, and with no reported rebound anxiety after discontinuation. These findings have not been replicated under Western RCT methodology, and direct head-to-head comparisons with benzodiazepines at equivalent anxiolytic doses have not been performed.
Research by Kozlovskii and Danchev (2002, 2003) published in the Bulletin of Experimental Biology and Medicine reported that Selank improved memory consolidation and learning performance in rat models, potentially through its effects on BDNF and monoamine pathways. Rats showed improved performance in passive avoidance and Morris water maze tests. Human cognitive data is early-stage and limited to Russian clinical reports.
As a tuftsin derivative, Selank retains immunomodulatory properties. Ershov et al. (2009) demonstrated gene expression changes in 84 immune-related genes in human leukocytes after Selank exposure. The research suggests influence on innate immune responses, though this application is secondary to its primary neurological use.
In its approved pharmaceutical form in Russia, Selank is administered as a nasal spray (0.15% solution). This route provides direct access to the central nervous system via the olfactory and trigeminal nerve pathways, bypassing the blood-brain barrier more effectively than oral administration.
Some research has also studied subcutaneous injection. Nasal delivery is the more common route in both the approved product and research contexts.
This is research context, not prescribing guidance. Selank is handled consultation-first and this information should not be interpreted as a dosing recommendation.
Based on the available data from clinical research and pharmaceutical use in Russia.
Russian pharmaceutical data, reviewed by Seredenin and Kozlovskaya (2012), reports a favorable safety profile with no reported dependence or withdrawal symptoms, a notable distinction from benzodiazepines and other traditional anxiolytics. Preclinical toxicology studies found no mutagenic or teratogenic effects. Western peer-reviewed safety data is limited, so this should be interpreted with that caveat.
Consult a healthcare provider before considering any peptide therapy. This information is educational and does not replace medical advice.
Selank is not an FDA-approved drug in the United States and is not currently on FDA’s 503A Bulks List. It was not among the peptides FDA’s Pharmacy Compounding Advisory Committee reviewed on July 23–24, 2026.
It is approved as a pharmaceutical product in Russia for anxiety and neurasthenia. In the US, it has no FDA approval as a drug, and its Category 2 bulk substance classification prevents compounding.
Reclassification to Category 1 is expected as part of the broader HHS peptide review, but no formal action has been taken. Gray-market vendors sell products labeled as Selank, but these are unregulated and lack pharmaceutical-grade quality controls.
Supports cellular energy production and cognitive function. NAD+ plays a direct role in brain energy metabolism and neuroprotective pathways. Physician-prescribed and delivered to your door.
Get startedGrowth hormone-releasing peptide. GH supports deep sleep, cognitive recovery, and overall brain health. Physician-prescribed and shipped to your door.
Get startedDeep dives
Research-backed articles covering specific topics in depth.
One week in, the poster reports the most stable his brain has been, on 400 mcg injected subcutaneously each morning for generalized anxiety and panic disorder, with a single mild headache after the first dose and none since. He names the confound himself: he started Prozac in January and credits it with much of the improvement, so a week of added Selank cannot be separated from an SSRI still taking effect, and Selank is not an FDA-approved drug.
Posted on Reddit
Selank is not currently on FDA's 503A Bulks List. PepScribe's programs and Tier 1 peptides give a clinician the room to review your goals and the options open to you.
